Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provide informed consent or assent when appropriate, as determined by the participant's age and individual site and local standards
Prescribed or continued risdiplam based on clinical judgment of prescriber, as per the risdiplam (Evrysdi) USPI, after U.S. FDA approval (07 August 2020)
You may not be if
Hypersensitivity to risdiplam
Participated in a registrational trial for risdiplam (i.e., Firefish \[NCT02913482\], Sunfish \[NCT02908685\], Jewelfish \[NCT03032172\], and Rainbowfish \[NCT03779334\])
Clareo Health | Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
